Aethlon Medical, Inc.

AEMD Q3 2026

Reported: 2026-02-13

Aethlon Medical demonstrated steady progress in its Hemopurifier platform amidst ongoing clinical trials and strategic operational efficiencies in Q3 FY2026.

Key takeaways

Continued enrollment and treatment efforts in the Australian oncology trial indicate positive patient interest and safety outcomes, with no serious adverse events reported so far.
Ongoing operating expense reductions year-to-date reflect disciplined cost management and financial prudence.
Advancements in EV research support the Hemopurifier's potential as a multi-indication therapeutic platform, broadening its future applications.
Collaboration with Stavro on simplifying the Hemopurifier treatment procedure aims to enhance clinical flexibility and accessibility.
Exploration of the Hemopurifier's role in addressing other health conditions, including Long COVID and various autoimmune diseases, suggests opportunities for pipeline expansion.

View recap

Applied Materials, Inc.

AMAT Q1 2026

Reported: 2026-02-13

Applied Materials, Inc. reported robust revenues in Q1 2026, buoyed by strong demand across AI, foundry-logic, and memory sectors, while executing on strategic investments to enhance long-term growth.

Key takeaways

Revenue growth driven by sustained AI-related demand and node migrations across key sectors.
Strong operational discipline led to favorable cash flow generation and shareholder capital returns through buybacks and dividends.
Continued investments in R&D and capacity expansion to support emerging technologies, particularly in advanced packaging and memory solutions.
Gross margins expected to improve as product mix normalizes and supply chains stabilize.
Growing momentum in regions such as the U.S. and Taiwan indicates strong market resilience and opportunity.

View recap

AtlasClear Holdings, Inc.

ATCH Q2 2026

Reported: 2026-02-13

AtlasClear Holdings reported a remarkable 84% revenue growth year-over-year in Q4 2025, achieving positive net income of $6.8 million and solidifying a strengthened financial position with stockholders' equity rising to $21.7 million.

Key takeaways

Revenue reached $5.1 million, primarily driven by increased client activity and diversification of income streams.
Stockholders’ equity improved significantly from a deficit of $6.8 million to a positive $21.7 million, marking a critical turnaround.
Liquidity strengthened with $46.2 million in cash and restricted cash, enhancing operational flexibility.
The company's clearing platform, Wilson-Davis, continues to serve as the core engine for growth, catering to an expanding client base.
AtlasClear is strategically focused on sustained growth by refining client experience and onboarding new firms selectively.

View recap

Birkenstock Holding plc

BIRK Q1 2026

Reported: 2026-02-13

Birkenstock Holding plc reported a robust Q1 fiscal 2026, achieving €402 million in revenues—an 11% increase on a reported basis and 18% in constant currency, significantly surpassing guidance.

Key takeaways

B2B sales surged 24% in constant currency, outperforming DTC, which grew 12%.
APAC revenues rose 37% in constant currency, reflecting strong growth potential in underpenetrated markets.
Closed-toe products, led by key silhouettes, made up nearly 60% of revenue, indicating successful brand expansion beyond sandals.
The company remains on track to open 40 new stores this fiscal year, enhancing its direct-to-consumer presence.

View recap

Legacy Education Inc.

LGCY Q2 2026

Reported: 2026-02-13

Legacy Education Inc. reported a robust second quarter for fiscal 2026, achieving a 40.7% year-over-year revenue growth alongside significant net income and adjusted EBITDA increases, positioning the company well for continued expansion in the growing healthcare education sector.

Key takeaways

Revenue surged to $19.2 million, marking the 14th consecutive quarter of double-digit growth.
Net income rose 46% to $2 million, translating to earnings of $0.15 per diluted share.
Student enrollment grew 6.8% year-over-year, reaching a total of 3,234, driven by new program rollouts and effective marketing strategies.
Strong operational momentum was highlighted by the successful launch of the MRI program and upcoming cardiac sonography offerings, enhancing future growth potential.
Accreditation milestones, including a six-year reaccreditation for Integrity College of Health, reinforce the quality of education and institutional compliance.

View recap

Research Solutions, Inc.

RSSS Q2 2026

Reported: 2026-02-13

Research Solutions reported mixed results for Q2 fiscal 2026, with total revenue slightly declining year-over-year, but strong growth in its B2B platform segment and improvements in profitability metrics.

Key takeaways

Total revenue decreased to $11.8 million, slightly down from $11.9 million in Q2 fiscal 2025, attributed mainly to churned accounts and decreased transaction volume.
B2B ARR increased 14% year-over-year, reaching $15.3 million, driven by a record 47 new platform deployments.
Gross profit rose 6% to $6.2 million, with gross margin improving to 52.4%, thanks to a shift towards higher-margin platform revenue.
Net income turned positive at $547,000 compared to a loss of $2 million in the prior year, indicating improved operational efficiency.
Q2 saw a 14% increase in platform subscription revenue, highlighting robust customer engagement in the B2B segment despite challenges in B2C subscriptions.

View recap

thyssenkrupp AG

TKA.DE Q1 2026

Reported: 2026-02-13

thyssenkrupp reported a solid start to fiscal year '25-'26, achieving an uptick in EBIT despite an 8% decline in sales, while confirming its full-year guidance amid a challenging market environment.

Key takeaways

Adjusted EBIT increased to EUR 211 million, surpassing last year's performance by EUR 20 million.
Sales dropped to EUR 7.2 billion, reflecting ongoing weak demand and market challenges.
Free cash flow showed a typical seasonal decline of EUR 1.5 billion, but full-year guidance for cash flow before M&A remains unchanged.
Workforce reduction progressed as planned, with FTE down by approximately 1,100 in Q1.
Strategic milestones include ongoing negotiations for Steel Europe’s majority holding and advancements in the green transformation efforts.

View recap

VERBIO Vereinigte BioEnergie AG

VBK.DE Q2 2026

Reported: 2026-02-13

Verbio SE reported a strong first half of fiscal year 2025-2026, with robust revenue growth and improved EBITDA driven by higher production volumes and favorable market conditions.

Key takeaways

Group EBITDA increased to €30.1 million in Q2, up from €15.4 million in Q1, marking a significant quarter-over-quarter recovery.
Total biodiesel output reached 311,000 tonnes, with European production setting a new record despite a planned seasonal shutdown in Canada.
Increased demand for greenhouse gas quotas contributed to higher revenue, offsetting elevated material costs effectively.
Operating cash flow improved significantly to €35.6 million, while net debt rose to €173 million due to strategic investments.
Full-year EBITDA expectations have been raised to the upper end of previous guidance, indicating a strong outlook for the remainder of the fiscal year.

View recap

VistaGen Therapeutics, Inc.

VTGN Q3 2026

Reported: 2026-02-13

Vistagen Therapeutics reported significant progress in its clinical-stage programs, highlighted by the completion of the PALISADE-3 Phase III trial and continued advancements in its women's health product candidate, refisolone.

Key takeaways

Completed the randomized portion of the PALISADE-3 Phase III trial focused on social anxiety disorder, with ongoing enhancements for the PALISADE-4 trial.
Received USAN adoption for refisolone, a hormone-free treatment candidate for menopause-related symptoms, with an IND submission planned for H1 2026.
Cash position stands at $61.8 million, supported by company-wide cash preservation measures to ensure operational efficiency and strategic flexibility.

View recap

Westpac Banking Corporation

WBC.AX Q1 2026

Reported: 2026-02-13

Westpac reported a solid Q1 FY '26 performance, with net profit excluding notable items up 5% and strong deposit growth, highlighting continued operational momentum amidst a competitive lending environment.

Key takeaways

Net interest income rose by 2%, while noninterest income declined by 4%, reflecting market headwinds.
Customer deposits increased by $12 billion, with household deposits up 3% and business transactional deposits up 4%.
Loan growth of $22 billion was driven by a diversification strategy across customer segments.
Credit quality metrics improved, with a decrease in stressed exposures and low credit impairment charges at 6 basis points of average gross loans.
CET1 capital ratio remained strong at 12.3%, despite a reduction due to dividend payments.

View recap

Beyond Air, Inc.

XAIR Q3 2026

Reported: 2026-02-13

Beyond Air reported a remarkable 105% year-over-year revenue increase to $2.2 million, driven by growing adoption of its LungFit PH system, and strategically strengthened its balance sheet through the sale of its NeuroNOS subsidiary.

Key takeaways

Achieved significant revenue growth, with quarterly revenue reaching $2.2 million, reflecting strong market demand and increased hospital adoption.
Over 45 hospitals currently utilize the first-generation LungFit PH system, with customer retention exceeding 90%.
Completed the initial sale of LungFit PH to a VA Medical Center, marking a key milestone in expanding the company’s presence in federal healthcare systems.
Expanded international distribution, now covering 40 countries, enhancing the company’s global footprint for long-term growth.
Preparing for the anticipated FDA approval of the second-generation LungFit PH system, expected to enhance market reach and operational efficiency.

View recap

Earnings Recaps

Aethlon Medical, Inc.

Applied Materials, Inc.

AtlasClear Holdings, Inc.

Birkenstock Holding plc

Legacy Education Inc.

Research Solutions, Inc.

thyssenkrupp AG

VERBIO Vereinigte BioEnergie AG

VistaGen Therapeutics, Inc.

Westpac Banking Corporation

Beyond Air, Inc.

Community

Earnings Recaps

Aethlon Medical, Inc.

Applied Materials, Inc.

AtlasClear Holdings, Inc.

Birkenstock Holding plc

Legacy Education Inc.

Research Solutions, Inc.

thyssenkrupp AG

VERBIO Vereinigte BioEnergie AG

VistaGen Therapeutics, Inc.

Westpac Banking Corporation

Beyond Air, Inc.

Community

Trending This Week

Notifications